Member Info for Morgank

This stock has legs with a current SP target of 110p and positive news flow going forward

AGM. Statement indicates funded to Dec 2019

A good day and steady progress breaking the 60p milestone and closing above.

Think they are all sells based on bid/offer @ the time that’s why SP fallen back, maybe sellers thinking they can buy the offer up to 10 April @3p but if its over subscribed then they may fail to get what they ask for !

Much selling this morning on NEX

Yes here’s hoping PI’s load up their ISA’s and SIP’s in the new tax year starting next week in anticipation of the steady move up in the SP

2 x 2mil trades reported this morning @ 15:00:18 yesterday looks like buys @3.05p

There was another 2 mil trade at that time yesterday preceded by a 6mil

If all valid that’s 12mil bought

RedT Energy PLC Completion of US Business Activities Divestment

Source: UK Regulatory (RNS & others)
TIDMRED

RNS Number : 2144V

RedT Energy PLC

05 April 2019

This announcement contains inside information

5 April 2019

redT energy plc

("redT" or the "Company")

Completion of US Business Activities Divestment

Further to the announcement made on 14 March 2019, redT energy plc (AIM:RED), the energy storage solutions company, is pleased to announce that it has now completed the divestment of its legacy Camco business with the sale of its wholly owned subsidiary Camco International Group Inc. ('CIG'). This business provides project development and asset management services to biogas projects in the USA. Over the last three financial years this business has contributed GBP0.2 million per annum to group Results from Operating Activities.

CIG has been sold to an entity controlled by Jim Wiest, Managing Director of CIG. Cash receipts from the sale consist of a distribution of US$1.0 million to redT funded by a loan into CIG from a third party plus $0.5m of further consideration payable in two equal instalments, the first due 30 April 2019 and the balance due 31 July 2019. It was agreed that working capital balances, including cash of $0.5m, would remain in CIG as part of the sale resulting in a net cash benefit to redT as a result of the transaction of $1m. This will be used to fund the redT business during the Strategic Review announced on 14 March 2019. At the time of sale, CIG had net liabilities of US$0.3 million, including the US$1.0 million loan liability.

The divestment of US business activities constitutes a related party transaction under the AIM Rules. The Directors consider, having consulted with Investec, acting in its capacity as the Company's Nominated Adviser, that the terms of the sale are fair and reasonable insofar as the Company's shareholders are concerned.

Enquiries:


redT energy plc +44 (0)20 7121 6111
Neil O'Brien, Executive Chairman
Joe Worthington, Investor & Media
Relations

Investec Bank plc (Nominated Adviser
and Broker) +44 (0)20 7597 5970
Jeremy Ellis / Chris Sim / Alexander
Ruffman
VSA Capital (Joint Broker)
Andrew Monk / Andrew Raca / Simon
Barton +44 (0)20 3005 5000

Celicourt Communications (Financial
PR)
Mark Antelme / Jimmy Lea / Ollie
Mills +44 (0)20 7520 9266


Notes to Editors

About redT energy

redT energy plc are experts in energy storage, specialising in the design, manufacture, installation and operation of energy storage infrastructure which creates revenue alongside reliable, low-cost renewable generation for businesses, industry and electricity distribution networks. Using patented vanadium redox flow technology to store energy in liquid, redT's own energy storage machines can be run contin

It always happens, you just have to hang on for the big news then the sellers will be sorry

Gives hope

Angle PLC AACR 2019

Source: UK Regulatory (RNS & others)
TIDMAGL

RNS Number : 0679V

Angle PLC

04 April 2019


For immediate release 4 April 2019

ANGLE plc ("the Company")

ANGLE'S PARSORTIX SYSTEM SHOWCASED IN SIX POSTER PRESENTATIONS AT LEADING CANCER CONFERENCE AACR 2019

Customers publish data from four independent studies demonstrating success with ANGLE's Parsortix liquid biopsy system

ANGLE publishes detailed analytical performance data of Parsortix and HyCEAD Ziplex downstream analysis systems

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, today announces that its Parsortix(TM) system has been showcased by a number of customers in poster presentations at the American Association for Cancer Research conference (AACR) 2019, in Atlanta, Georgia, United States from 29 March to 3 April 2019.

In addition, ANGLE presented detailed performance data from the optimisation of its ovarian cancer assay for both its Parsortix and HyCEAD Ziplex systems at the conference.

Work by the University of Athens lead by Professor Evi Lianidou was particularly important as it demonstrated the superior performance of the Parsortix system in head and neck squamous cell carcinoma (HNSCC) in matched samples when compared with an antibody-based CTC enrichment approach. Superior sensitivity of Parsortix was demonstrated for the expression of multiple genes.

Expression of PD-L1 is of particular importance as it is the target for leading immunotherapy drugs including Nivolumab (Opdivo(R)) manufactured by Bristol Myers Squibb and Pembrolizumab (Keytruda(R)) manufactured by Merck. These drugs can be very effective for some patients. Only a minority of patients will respond and it is crucial to be able to accurately identify which ones. In the matched comparison of PD-L1 expression in 50 HNSCC patients, the Parsortix system identified 9/50 with PD-L1 expression whereas the antibody-based approach only identified 4/50. Around 1 in 5 patients may be expected to respond to PD-L1 immunotherapies so the Parsortix result is consistent with expected detection levels.

As well as this work by the University of Athens, ANGLE's Parsortix system has been showcased in the following poster presentations at AACR 2019:

Poster Presentations

1) University of Athens, Greece: Molecular characterisation of circulating tumor cells in head and neck squamous cell carcinoma: Direct comparison of a label-independent size-based microfluidic device with EpCAM-based CTC enrichment.

2) Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy: Molecular characterization of circulating tumor cells in cholangiocarcinoma patients: A new tool for treatment management?

3) Northwestern University, Chicago, United States: Increased chromatin heterogeneity in circulating tumor cells (CTCs) is associated with high levels of HER2 expression in metastatic breast cancer (MBC)

4) University of Athens, Greece: Detection of CK

To put that in perspective, a take over requires 20% holding @ new total issue of shares that’s 691.2 mil

https://news.sky.com/story/giant-batteries-to-be-built-in-oxford-after-the-city-wins-20m-in-green-funding-11682768

Looks like some end of UK tax year trading lots of selling and now some larger buys

Isn’t that how a market works ? Some sells to a buyer and vis versa

On what do you base that statement ?

You have to ask why OEM’s would put there future tech in the hands of a company with poor financial foundations ?

Great start to the day

RedT Energy PLC First UK grid project for redT

Source: RNS Non-Regulatory
TIDMRED

RedT Energy PLC

03 April 2019

3 April 2019

redT energy plc

("redT" or the "Company")

Oxford 'Superhub' launch marks first UK grid-scale project for redT

Largest deployment of flow machines in UK to support EV charging network

Further to the announcement of a signed purchase agreement to supply 72 units for a large UK grid project on 14(th) March, redT energy plc (AIM:RED), the energy storage solutions company, is pleased to provide an update on its role as part of a consortium of companies delivering an overall GBP41 million grid-scale project in Oxford, UK which will include 5MWh (72 units) of vanadium redox flow machines as part of a grid-connected 50MW Vanadium / Lithium-ion hybrid energy storage system............see RNS 3/4/19

More steady buying today